IPO - Lifeward Ltd.

Form Type: 424B4

Filing Date: 2025-06-26

Corporate Action: Ipo

Type: New

Accession Number: 000117891325002241

Filing Summary: Lifeward Ltd. is conducting a public offering of 4,000,000 ordinary shares and 4,000,000 accompanying warrants at a combined public offering price of $0.65 per share. Each warrant allows the purchase of one ordinary share at the same price and will expire five years from the initial exercise date. The company expects to close this offering on or about June 26, 2025, and it acknowledges potential risks posed by the absence of an active trading market for the warrants. The anticipated net proceeds from this offering are approximately $2.0 million, aimed at funding commercial efforts, working capital, and general corporate expenditures. The document emphasizes various risks associated with the investment, including the market's volatility and uncertainties surrounding raising additional financing as the company has an accumulated deficit and substantial doubt about continuing as a going concern. Lifeward trades on the Nasdaq under the symbol 'LFWD.'

Form Type: 8-K

Filing Date: 2025-06-26

Corporate Action: Ipo

Type: New

Accession Number: 000117891325002251

Filing Summary: On June 25, 2025, Lifeward Ltd. commenced a best efforts public offering of an aggregate of 4,000,000 ordinary shares and 4,000,000 warrants to purchase ordinary shares at a combined price of $0.65. The offering closed on June 26, 2025, with expected net proceeds of approximately $2.0 million for commercial efforts and working capital. The company entered into a Purchase Agreement with institutional investors, agreeing to not issue any additional shares for 30 days and to restrictions on variable rate transactions for one year. The Placement Agent for the offering, H.C. Wainwright & Co., LLC, will receive a cash fee, management fee, and expense reimbursements, and will also receive warrants to purchase 240,000 ordinary shares.

Form Type: S-1/A

Filing Date: 2025-06-25

Corporate Action: Ipo

Type: New

Accession Number: 000117891325002225

Filing Summary: Lifeward Ltd. is a medical device company focused on developing advanced rehabilitation solutions, including the ReWalk Personal and Rehabilitation Exoskeleton devices for individuals with spinal cord injuries. The company has received FDA clearance for its device, enhancing its marketability. Lifeward is seeking to offer up to 4,000,000 ordinary shares along with warrants as part of their public offering on the Nasdaq Capital Market, with a combined public offering price of $1.07 per share. The proceeds will be utilized immediately for the company's operations and future product development, including a pending product for stroke rehabilitation. The offering aims to attract investment and expand market penetration, particularly in the workers' compensation market via an exclusive agreement with CorLife, LLC. Lifeward is classified as a smaller reporting company under federal law, and investors are advised to consider the risks associated with the offering. The offering will close on July 30, 2025, unless an earlier termination occurs.

Form Type: S-1

Filing Date: 2025-06-20

Corporate Action: Ipo

Type: New

Accession Number: 000117891325002206

Filing Summary: Lifeward Ltd., a medical device company incorporated in Israel, is offering up to 4,000,000 ordinary shares and accompanying warrants to the public, following a Registration Statement filed with the SEC on June 20, 2025. The offering price for each ordinary share and accompanying warrant is set at $1.07, based on recent trading data from The Nasdaq Capital Market. This offering aims to fund the commercialization of its products, including advanced exoskeleton technologies designed for rehabilitation following spinal cord injuries. The company recently received FDA clearance for enhancements to its existing devices and aims to expand its market presence in rehabilitation through agreements and acquisitions, including a recent acquisition of AlterG, which specializes in anti-gravity rehabilitation technologies. Lifeward is classified as a smaller reporting company, which allows it to adhere to reduced public company reporting requirements. The offering is scheduled to conclude on July 30, 2025, unless closed earlier at the company's discretion.

Form Type: DRS

Filing Date: 2025-05-27

Corporate Action: Ipo

Type: New

Accession Number: 000117891325001970

Filing Summary: On May 27, 2025, Lifeward Ltd. filed a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission, enabling the company to go public. The registration revolves around the sale of ordinary shares and warrants to purchase more ordinary shares. The filing highlights Lifeward's mission as a medical device provider focused on rehabilitation solutions, including notable products like the ReWalk exoskeleton for spinal cord injury patients. The company intends to expand its market reach, particularly in the workers’ compensation sector through a partnership with CorLife, aimed at enhancing the distribution of their ReWalk product. The company is also emphasizing its recent acquisition of AlterG, which enhances its portfolio in physical rehabilitation. The document outlines the company's operational strategies, product offerings, and addresses risk factors associated with investment in their securities. Lifeward is classified as a smaller reporting company, allowing it to fulfill certain reduced reporting obligations. The document also details the lack of an established market for its warrants, thereby impacting liquidity. Overall, this offering signifies Lifeward's expansion into broader markets and increased accessibility of its innovative rehabilitation solutions.

Form Type: CORRESP

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000491

Filing Summary: Lifeward Ltd. requests the acceleration of the effective date of its registration statement on Form S-1, designated as File No. 333-284843, to 4:05 p.m. Eastern Time on February 14, 2025. The request allows for the registration statement to become effective at the earliest possible convenience, with instructions for the Securities and Exchange Commission to confirm this event with the company's counsel. The communication is in compliance with Rule 461 under the Securities Act of 1933.

Form Type: S-1

Filing Date: 2025-02-11

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000411

Filing Summary: Lifeward Ltd. filed for registration with the SEC under Form S-1 on February 11, 2025. The filing aims to sell up to 1,927,274 Ordinary Shares, par value NIS 1.75 per share, through the resale by certain selling shareholders. This includes warrants for 1,818,183 Ordinary Shares initially issued in a private placement on January 7, 2025, and warrants for 109,091 Ordinary Shares provided to H.C. Wainwright & Co., LLC as compensation for their role in the placement. The offering is a part of a larger private placement and registered direct offering, but the company will not receive proceeds from the resale by the shareholders. However, proceeds from future warrant exercises could amount to approximately $5.4 million. The filing specifies that the registration statement is tentative and not yet effective, indicating that the selling shareholders cannot sell these securities until the registration is effective.